FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Immunohistochemistry Assay, Antibody, Anaplastic Lymphoma Kinase
PMA: P140025
·
Supplement: S024
·
Decision Mar 12, 2025
Classifications
1
FEI Numbers
1
Registration Numbers
1
Basic Information
- Device Name
- Immunohistochemistry Assay, Antibody, Anaplastic Lymphoma Kinase
- Trade Name
- VENTANA ALK (D5F3) CDx Assay
- PMA Number
- P140025
- Supplement Number
- S024
- Device Class
- FDA Class 3
- Product Code
- PKW
- Generic Name
- Immunohistochemistry assay, antibody, anaplastic lymphoma kinase
- Medical Specialty
- Unknown
- Advisory Committee
- Pathology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- March 12, 2025
- Date Received
- December 8, 2023
- Supplement Type
- Normal 180 Day Track
- Supplement Reason
- Change Design/Components/Specifications/Material
- Expedited Review
- N
Advisory Committee Statement
Approval for the migration of the VENTANA ALK (D5F3) Assay from BenchMark ULTRA to BenchMark ULTRA PLUS instrument
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| PKW | Immunohistochemistry Assay, Antibody, Anaplastic Lymphoma Kinase | FDA class 3 | Unknown |